IP Library Granted Patent US 8,407,095
Granted Patent B2
US 8,407,095 · App. 13/209,970 · Granted Mar 26, 2013

Method of delivering a pharmaceutical product via a medium

Inventors: David W. Cunningham (Raleigh, NC); John M. Harden (Oxford, NC); William N. Engle (Raleigh, NC); Charles W. Reuben (Cary, NC)
Assignee: Trialcard Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,407,095
App. No.
13/209,970
Granted
Mar 26, 2013
Kind
B2
Abstract

One or more embodiments include a method of delivering a pharmaceutical product via a medium. The pharmaceutical product is associated with the medium and the medium assumes different values based on predetermined business rules. The method includes generating data in a database associated with a central computing station where the data identifies the medium and the product associated with the medium. The database is provisioned with the rules that determine the value of the medium. In response to the holder presenting the medium to a provider of the product for purposes of obtaining the product, a communication from the provider is received identifying the medium. A value for the medium is established based on the rules provisioned in the database. The value of the medium is updated, and that updated value is recorded in the database in response to the provider providing the product to the holder of the medium.

Claims (22)

1. A method of delivering a pharmaceutical product via a medium where the pharmaceutical product is associated with the medium and the medium assumes different values based on predetermined business rules, the method comprising:

generating data in a database associated with a central computing station where the data identifies the medium and the pharmaceutical product associated with the medium;

provisioning the database with the predetermined business rules that determines the value of the medium;

in response to a holder presenting the medium to a provider of the pharmaceutical product for purposes of obtaining the pharmaceutical product, receiving at the central computing station a communication from the provider identifying the medium presented to the provider by the holder;

establishing a value for the medium, using the central computing station, based on the predetermined business rules provisioned in the database; and

updating the value of the medium and recording the updated value in the database, using the central computing station, in response to the provider of the pharmaceutical product providing the pharmaceutical product to the holder of the medium.

2. The method of claim 1 wherein the provisioned business rules that determine the value of the medium base the value of the medium on a co-payment of the holder.

3. The method of claim 1 wherein the value of the medium varies with a co-payment of the holder and wherein the method includes in response to the holder presenting the medium to the provider, determining the holder's co-payment for the pharmaceutical product associated with the medium.

4. The method of claim 1 further comprising communicating the value of the medium to the provider whereupon the holder utilizes the medium to purchase the pharmaceutical product associated with the medium.

5. The method of claim 1 wherein initially the medium assumes an inactive state and wherein subsequently the medium assumes an active state, and wherein the medium in an inactive state is ineffective to purchase the pharmaceutical product associated with the medium.

6. The method of claim 1 including recording a unique identifier in the database where the unique identifier is associated with the medium.

7. The method of claim 1 further including:

assigning an inactive status to the medium such that while assuming the inactive status the pharmaceutical product associated with the medium may not be redeemed or partly redeemed with the medium;

recording the inactive status in the database; and

activating the medium by changing the status of the medium from an inactive state to an active state and recording the change of the status in the database.

8. The method of claim 1 wherein the value of the medium varies with a co-payment of the holder and wherein the method includes in response to the holder presenting the medium to the provider, determining the holder's co-payment for the pharmaceutical product associated with the medium; and communicating the value of the medium to the provider whereupon the holder utilizes the value to purchase the pharmaceutical product associated with the medium.

9. The method of claim 8 further including:

assigning an inactive status to the medium such that while assuming the inactive status the pharmaceutical product associated with the medium may not be redeemed or partly redeemed with the medium;

recording the inactive status in the database; and

activating the medium by changing the status of the medium from an inactive state to an active state and recording the change of the status in the database.

10. The method of claim 1 wherein based on the medium and the business rules provisioned in the database, communicating the value of the medium to the provider whereupon the holder utilizes the value to purchase the pharmaceutical product associated with the medium; and wherein initially the medium assumes an inactive state and wherein subsequently the medium assumes an active state, and wherein the medium in an inactive state is ineffective to purchase the pharmaceutical product associated with the medium.

11. The method of claim 10 including recording a unique identifier in the database where the unique identifier is associated with the medium.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded May 20, 2025
From: BLUE OWL CAPITAL CORPORATION (FKA OWL ROCK CAPITAL CORPORATION), AS COLLATERAL AGENT; BLUE OWL FIRST LIEN MASTER FUND LP (FKA OWL ROCK FIRST LIEN MASTER FUND, L.P.), AS SUCCESSOR AGENT
To: MERCALIS INC. (FKA TRIALCARD INCORPORATED)
Reel/Frame 071168/0587 →
RELEASE OF SECURITY INTEREST Recorded Nov 14, 2017
From: MADISON CAPITAL FUNDING LLC, AS AGENT
To: TRIALCARD INCORPORATED
Reel/Frame 044124/0366 →
SECURITY INTEREST Recorded Nov 14, 2017
From: TRIALCARD INCORPORATED
To: OWL ROCK CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 044117/0430 →
RELEASE OF SECURITY INTEREST Recorded Oct 26, 2016
From: FIFTH STREET MANAGEMENT LLC
To: TRIALCARD INCORPORATED
Reel/Frame 040142/0377 →
SECURITY INTEREST Recorded Oct 26, 2016
From: TRIALCARD INCORPORATED
To: MADISON CAPITAL FUNDING LLC, AS AGENT
Reel/Frame 040143/0914 →
SECURITY INTEREST Recorded Dec 31, 2014
From: TRIALCARD INCORPORATED
To: FIFTH STREET MANAGEMENT LLC
Reel/Frame 034606/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2014
From: CUNNINGHAM, DAVID W.; HARDEN, JOHN M.; ENGLE, WILLIAM N.; REUBEN, CHARLES W.
To: TRIALCARD SYSTEMS, INC.
Reel/Frame 034591/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2014
From: TRIALCARD SYSTEMS, INC.
To: TRIALCARD INCORPORATED
Reel/Frame 034591/0934 →
Continuity (4)
Continuation 11459070 · Jul 21, 2006
Division 10098700 · Mar 15, 2002
Continuation In Part 09558260 · Apr 25, 2000
Related Publication 20110301973A1 · Dec 8, 2011